Post-hoc analysis of long-term outcomes in patients with CR, PR, or SD to pembrolizumab (pembro) or platinum-based chemotherapy (chemo) as 1L therapy for advanced urothelial carcinoma (UC) in KEYNOTE-361.

Date
2021
Author
Fradet, Yves
Loriot, Yohann
Alva, Ajjai Shivaram
Csoszi, Tibor
ÖZGÜROĞLU, Mustafa
Matsubara, Nobuaki
Geczi, Lajos
Cheng, Susanna Y.
Oudard, Stephane
Vulsteke, Christof
Morales-Barrera, Rafael
Flechon, Aude
Gunduz, Seyda
Rodriguez-Vida, Alejo
Mamtani, Ronac
Yu, Evan Y.
Liu Chih-Chin, Liu Chih-Chin
Imai, Kentaro
Moreno, Blanca Homet
Powles, Thomas
Metadata
Show full item record
URI
http://hdl.handle.net/20.500.12627/169488
https://doi.org/10.1200/jco.2021.39.6_suppl.435
Collections